2-peptide research blend in one vial: CJC-1295 without DAC + GHRP-2. A growth-hormone secretagogue stack pairing the GHRH analog CJC-1295 with the potent ghrelin-mimetic GHRP-2 — two receptors, one amplified GH pulse.
A blend has one whole-vial purity, but the number that decides what you're holding is the net content of each component — an HPLC run resolves a separate peak for each. So we verify CJC-1295 + GHRP-2 component by component. Each links to its own compound page, where its full independent testing lives.
| Component | Typical mg | Role in the blend | Verified purity | |
|---|---|---|---|---|
| CJC-1295 without DAC | varies | GHRH analog — raises GH pulse amplitude | 99.5% · 295 tests | View testing → |
| GHRP-2 | varies | Ghrelin mimetic — pulse frequency + somatostatin suppression; potent | 99.2% · 38 tests | View testing → |
Composition varies by vendor. The components above are consistent across shops, but the milligrams and ratio are not — always dose by the individual component amounts printed on your vial, never by a generic “blend dose.”
A blend is the single hardest product to trust — the whole-vial purity tells you the material is clean, but not whether every peptide is present in the right amount. Two questions decide that, and both are answerable in a lab.
Mass spec (or a clean HPLC peak per compound) confirms each peptide is in the vial — not one short, not a cheaper substitute standing in for the expensive one.
Tested milligrams vs. labelled milligrams, per component. This is where blends fail quietly — one component underdosed to pad margin while the vial still “contains” everything.
Tests run on a CJC-1295 + GHRP-2 vial as sold — broken down per component. This is the data no shop and no competitor publishes.
CJC-1295 + GHRP-2 is new to the library. Have a COA for a CJC-1295 + GHRP-2 vial? Add it — every submission maps back to the 2 component compounds automatically.
Submit a CJC-1295 + GHRP-2 lab testUntil more CJC-1295 + GHRP-2 vials are tested, the strongest signal is how each component performs in single-compound testing across the shops we track. Tap any card for its full data.
Last Updated: August 2026
This is a classic growth-hormone secretagogue pairing: the GHRH analog CJC-1295 (without DAC) with the ghrelin-mimetic GHRP-2. The two act on different receptors, and the combination is used in research contexts for the synergy described below. It is research-use-only, not an approved product, and CJC-1295 has no lawful pharmacy-compounding pathway — the FDA's Pharmacy Compounding Advisory Committee recommended against adding it to the 503A bulk-substances list ("do not include") in December 2024, and it is not on the Category 1 list eligible for compounding. GHRP-2 sits on the FDA's active Category 2 bulk-substances list under the 503B outsourcing-facility route — substances flagged as potentially presenting significant safety risks — and was not among the twelve peptides removed from Category 2 in April 2026. Both components are prohibited at all times in sport by the World Anti-Doping Agency under Section S2.2.4 of the Prohibited List (growth-hormone-releasing factors and secretagogues).
A GHRH analog like CJC-1295 increases the amplitude of the GH pulse, while GHRP-2 acts on the separate ghrelin receptor to increase pulse frequency and suppress somatostatin (the "brake") — together producing a larger, more synergistic GH release than either alone; GHRP-2's particular profile is potent GH stimulation with less appetite drive than GHRP-6, though it can slightly raise cortisol and prolactin. This is a mechanistic rationale, not a clinically-validated combination outcome.
The combination is not an approved product and is research-use-only; verify each labeled component's identity and purity via HPLC and mass-spec. Peptigrity collects independent third-party Certificates of Analysis for the CJC-1295 + GHRP-2 blend from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. Tests come from independent labs such as Janoshik Analytical, Freedom Diagnostics, and Chromate; the trust score weights lab purity and reviews equally (50/50). See how to read lab results.
Educational information only; not medical advice. This is a research-use-only stack, not an approved therapy. Consult a qualified healthcare provider. Peptigrity does not sell, endorse, or recommend products or vendors.
In a blend you can only set the dose of one component — the rest follow the fixed ratio. Our calculator does that math so you don't underdose the peptide you actually care about.
Enter each component's milligrams and your BAC water — get per-component units for one syringe draw.
Open the blend calculator →How much bacteriostatic water, mixing without shaking, storage, and shelf life once mixed.
Read the reconstitution guide →They act on two different receptors (GHRH and ghrelin), producing a larger, synergistic GH release No controlled clinical trial of the CJC-1295 + GHRP-2 combination has been published as of August 2026; the case for stacking a GHRH analog with a ghrelin-mimetic GHRP is mechanistic — drawn from how each component behaves alone — not from any trial of the blend itself. ?term=CJC-1295+GHRP-2 than either alone.
GHRP-2 is potent with less appetite stimulation; GHRP-6 drives stronger hunger. Both are ghrelin mimetics.
No — research-market material is RUO and both components are banned in sport (WADA). Verify local rules.
No. Peptigrity is an independent review platform, not a medical authority.